Dave, Chris makes a valid point, which was strongly supported by Gerald's statements and slides during the call.

I am less concerned after the call about the LymPro revenue discrepancy. It's going to be a non-issue for shareholders based on what was revealed in the call. LymPro will be either sold or spun off in the diagnostics division spin-off in 2015. It's in the presentation.